Get the Stockscreener App
58.51
2.90%
-1.75
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $58.51, with a volume of 2.26M.
It is down -2.90% in the last 24 hours and down -4.71% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$60.26
Open:
$60.57
24h Volume:
2.26M
Relative Volume:
1.04
Market Cap:
$9.12B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
62.24
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
-5.14%
1M Performance:
-4.71%
6M Performance:
+13.55%
1Y Performance:
-23.70%
1-Day Range:
$58.24
$60.59
1-Week Range:
$58.24
$61.69
52-Week Range:
$46.01
$79.28
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
612-379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
58.51 | 9.39B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-25 | Upgrade | Citigroup | Neutral → Buy |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jul-09-25 | Initiated | TD Cowen | Buy |
| May-30-25 | Initiated | Wells Fargo | Overweight |
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
4D Advisors LLC Makes New $2.06 Million Investment in Bio-Techne Corp $TECH - MarketBeat
GMP Cytokine Market and Competition Outlook to 2031: Growing at 8.4% CAGR, Led by Bio-Techne, PeproTech, CellGenix Among OthersResearchAndMarkets.com - The AI Journal
Osterweis Capital Management Inc. Has $7.70 Million Stake in Bio-Techne Corp $TECH - MarketBeat
Cerity Partners LLC Boosts Stake in Bio-Techne Corp $TECH - MarketBeat
Here’s Why BioTechne (TECH) Traded Lower in Q3 - Yahoo Finance
Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology - Investing News Network
Bio-techne and Wyss Center partner to develop automated 3D multiomics - Investing.com
Bio-Techne (NASDAQ: TECH) and Wyss Geneva to develop automated 3D multiomics workflow - Stock Titan
Does Bio-Techne’s Recent Weakness Offer an Opportunity After Its Cell and Gene Therapy Push? - Yahoo Finance
Bio-Techne Announces Expanded Launch Of Next-Generation Leo System - Nasdaq
Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein Analysis - Investing News Network
Bio-techne ships enhanced Leo System with expanded detection capabilities - Investing.com
Bio-Techne (NASDAQ: TECH) debuts Leo system with dual-channel fluorescence - Stock Titan
Transcript : Bio-Techne Corporation Presents at 53rd Annual Nasdaq Investor Conference, Dec-09-2025 09 - marketscreener.com
Arrowstreet Capital Limited Partnership Has $18.94 Million Stake in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp. stock outperforms competitors despite losses on the day - MarketWatch
Cresset Asset Management LLC Boosts Holdings in Bio-Techne Corp $TECH - MarketBeat
Brown Capital Management LLC Sells 94,825 Shares of Bio-Techne Corp $TECH - MarketBeat
1832 Asset Management L.P. Takes $7.72 Million Position in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corporation (TECH): A Bull Case Theory - Finviz
Norges Bank Buys New Stake in Bio-Techne Corp $TECH - MarketBeat
Russell Investments Group Ltd. Sells 23,984 Shares of Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp $TECH Holdings Reduced by Hsbc Holdings PLC - MarketBeat
How analysts revise price targets for Bio Techne Corporation (TE1) stockWeekly Market Report & Accurate Intraday Trading Signals - Newser
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Bio-Techne Corp $TECH Position Increased by Granite Investment Partners LLC - MarketBeat
Can Bio Techne Corporation stock reach $100 price targetWeekly Profit Report & AI Forecast Swing Trade Picks - Newser
Will Bio Techne Corporation (TE1) stock gain from green policies2025 Volatility Report & Real-Time Chart Pattern Alerts - Newser
How Bio Techne Corporation stock compares to market leadersQuarterly Investment Review & Weekly Watchlist of Top Performers - Newser
Edgestream Partners L.P. Has $11.81 Million Holdings in Bio-Techne Corp $TECH - MarketBeat
Prudential Financial Inc. Trims Holdings in Bio-Techne Corp $TECH - MarketBeat
Capital Fund Management S.A. Invests $4.89 Million in Bio-Techne Corp $TECH - MarketBeat
Mackenzie Financial Corp Raises Stock Holdings in Bio-Techne Corp $TECH - MarketBeat
Rhumbline Advisers Has $15.16 Million Stock Holdings in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp $TECH Shares Bought by JPMorgan Chase & Co. - MarketBeat
Grandeur Peak Global Advisors LLC Has $7.13 Million Stock Position in Bio-Techne Corp $TECH - MarketBeat
Charles Schwab Investment Management Inc. Boosts Position in Bio-Techne Corp $TECH - MarketBeat
Is Bio Techne Corporation stock supported by strong cash flows2025 Major Catalysts & Advanced Technical Analysis Signals - BỘ NỘI VỤ
Bio-Techne Corp $TECH Shares Sold by Neuberger Berman Group LLC - MarketBeat
Legal & General Group Plc Cuts Position in Bio-Techne Corp $TECH - MarketBeat
XTX Topco Ltd Boosts Position in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne (TECH): Assessing Valuation After ACA Subsidy Extension Buzz Boosts Investor Sentiment - simplywall.st
Bio-Techne (TECH): Evaluating Valuation After ACA Subsidy Extension Boosts Market Sentiment - Yahoo Finance
Swiss National Bank Has $15.52 Million Holdings in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Braces for a Biotech Funding Revival—Is a Major Upswing Ahead? - Smartkarma
SG Americas Securities LLC Sells 39,245 Shares of Bio-Techne Corp $TECH - MarketBeat
Ensign Peak Advisors Inc Trims Holdings in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp $TECH Shares Acquired by American Century Companies Inc. - MarketBeat
Rhenman & Partners Asset Management AB Takes Position in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp (TECH) Stock Forecasts - Yahoo! Finance Canada
Bio-Techne Corp. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):